Institut Pasteur De Lille

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Centre Hospitalier Régional Universitaire De Lille

Université Du Droit Et De La Santé De Lille 2

Université De Lille

Inserm (institut National De La Sante Et De La Recherche Medicale)

Gilles Riveau

Camille Locht

Nathalie Mielcarek

Andre Capron

Franco Menozzi

Monique Capron

Mohamed El Nady

Jean-Frederic Colombel

Genevieve Renauld

Francoise Jacob-Dubuisson

Odile Poulain-Godefroy

Andr&eacute; Capron

The present invention relates to a product selected from a protein, a fragment of the protein, a derived sequence and a homologous sequence of the protein, the protein including or being constituted by the 28 kDa glutathione S-transferase protein from a schistosome selected fromrepresented respectively by the sequences SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 for the use thereof in the treatment of an inflammatory autoimmune disease generating a response of type Th1 and/or Th17.

28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response

A recombinant DNA containing a sequence (1) coding for a polypeptide heterologous to a filamentous haemagglutinin of(Fha) fused within the reading frame to a sequence (2) located upstream from the first sequence. Sequence (2) codes for at least part of the Fha precursor, which part comprises at least the N-terminal region of a truncated mature Fha protein, which contains the interaction site of Fha and heparin and the secretion domain. This Fha protein is under the control of a promoter recognized by the cell polymerases ofand is inserted into acell culture, is expressed in the culture and excreted into the cell culture medium. The invention uses both the abilities ofand particularlyto secrete or surface expose the heterologous polypeptide fused to the Fha portion corresponding to sequence (2), which does not appear to produce extracellular proteases, and the ease with which filamentous haemagglutinins can be isolated from otherproteins.

RECOMBINANT PROTEINS OF FILAMENTOUS HAEMAGGLUTININ OF BORDETELLA, PARTICULARLY BORDETELLA PERTUSSIS, METHOD FOR PRODUCING SAME, AND USES THEREOF FOR PRODUCING FOREIGN PROTEINS OF VACCINATING ACTIVE PRINCIPLES

The invention concerns a Bordetella strain deficient in the production of toxin and expressing a hybrid protein comprising at least part of the filamentous hemagglutin (FHA) and at least part of a protein heterologous to FHA. The gene coding for the toxin has been eliminated, or at least partially deleted or mutated so as to produce an inactive toxin. This strain can be used as vaccine. The invention also concerns liposomes containing at least part of the FHA protein and at least one protein heterologous to the FHA protein, and the use of FHA for the stimulation of immune responses.

Bordetella strain expressing the FHA hybrid, liposomes and vaccines

Growing community of inventors

Phalempin, France

Gilles Riveau